Whan In Pharm Co.,Ltd.
016580.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$188.17B
Close$
$-2886.36
127.9% downside
Current Fair Value
127.9% downsideOvervalued by 127.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $188.17 Billion |
|---|---|
| Enterprise Value | $132.49 Billion |
| Dividend Yield | $300.00 (2.95%) |
| Earnings per Share | $857 |
| Beta | 0.2 |
| Outstanding Shares | 18,600,000 |
Return
| Return on Equity | 4.81% |
|---|---|
| Return on Assets | 4.24% |
| Return on Invested Capital | 5.36% |
Valuation & Multiples
| P/E Ratio | 9 |
|---|---|
| PEG | 6.36 |
| Price to Sales | 0.7 |
| Price to Book Ratio | 0.45 |
| Enterprise Value to Revenue | 0.48 |
| Enterprise Value to EBIT | 5.8 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$67.80 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$68.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Whan In Pharm Co.,Ltd.
671 employees
CEO: Wonbum Lee Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for me...